Welcome to our dedicated page for Airsculpt Technologies news (Ticker: AIRS), a resource for investors and traders seeking the latest updates and insights on Airsculpt Technologies stock.
AirSculpt Technologies, Inc. provides premium body contouring procedures through AirSculpt offices. Its AirSculpt method is a minimally invasive treatment for fat removal, skin tightening, targeted body sculpting, and fat transfer procedures that use a patient’s own fat cells.
Company news centers on operating results, same-center and same-store sales trends, case volume, revenue, adjusted EBITDA, guidance, marketing initiatives, new procedure categories, balance sheet activity, and governance changes. Updates also address the company’s positioning within aesthetics demand tied to GLP-1 use and its direct medical procedure services model.
AirSculpt Technologies has announced its initial public offering (IPO) of 7,000,000 shares at $11.00 per share. The offering consists of 2,173,913 shares issued by the company and 4,826,087 shares sold by existing stockholders. Underwriters have a 30-day option to buy an additional 1,050,000 shares. The shares are set to trade on NASDAQ under the symbol AIRS on October 29, 2021, with expected closing on November 2, 2021.
AirSculpt Technologies has announced the commencement of its initial public offering (IPO) roadshow, aiming to raise funds by offering 1,562,500 shares of common stock, alongside 8,437,500 shares from existing stockholders. The IPO price is set between $15.00 and $17.00 per share, with an option for underwriters to purchase up to 1,500,000 additional shares. The company intends to list its stock on Nasdaq under the symbol 'AIRS'. Morgan Stanley and Piper Sandler are leading the offering, with a registration statement already filed with the SEC but not yet effective.